

National PGD Template Work Plan

This document outlines the proposed work plans for the development of national Patient Group Directions (PGD) templates. The document is set out by work stream but to enable users unfamiliar with each of the work stream a drug index is included. The drug index can be used to find all PGD templates relating to a particular drug.

It is intended only to guide organisations on the PGD templates which the national 'Do Once' programme intends to produce. Release dates are not indicated as there are many variable factors which will affect the time it will take for each PGD template to reach the point of release.

When a PGD template has been released and is available the details of how it can be accessed (usually via a hyperlink) will be added to the work plan

As part of the national Do Once programme for developing PGD templates consideration is given by each workstream stakeholder group as to which clinical condition(s), clinical area(s) and drugs PGD templates will be developed for.

Part of this scoping work involves determining which PGD templates are not suitable for national development and the rationale for these decisions. This document outlines conditions, clinical areas or drugs where PGD templates will not be developed and the rationale for these decisions. The decisions made will be subject to regular review by the stakeholder group as national guidance is revised or developed and this document will be updated regularly to reflect these reviews.

February 2023

Contents

Index by Drug Name	3
Ambulance Trusts	5
PGD templates in the national programme:	5
Reproductive Health	6
PGD templates in the national programme:	6
PGD templates not included within the national programme:	6
Sexual health	7
PGD templates in the national programme:	7
Antimicrobials.....	8
PGD templates in the national programme:	8
PGD templates not included within the national programme:	8
Imaging contrast	9
PGD templates in the national programme:	9
Preventative Medicines in Pregnancy	10
PGD templates in the national programme:	10
Contrast imaging.....	9
PGD templates in the national programme:	9
Preventative Medicines in Pregnancy	10
PGD templates in the national programme:	10

Index by Drug Name

	Page number
Aciclovir (tablets)	7
Aspirin (tablets)	10
Azithromycin (tablets, capsules & suspension)	7
 Benzylpenicillin (injection)	 8, 10
Ceftriaxone (IM).....	7
Clotrimazole (cream)	7
Clotrimazole (pessaries).....	7
Combined Hormonal Contraceptives (tablets, ring, patch)	6
 Diazepam (rectal tubes)	 5
Diazepam emulsion (injection)	5
Diazepam solution (injection)	5
Doxycycline (capsules & disp. tablets)	7
 Etonorgestrel (implant)	 6
Fluconazole (capsules)	7
Flumazenil (injection)	5
Folic acid (tablets)	10
 Gadobenate dimeglumine (injection).....	 9
Gadobutrol (injection)	9
Gadoteric acid meglumine (injection)	9
Gadoteridol (injection)	9
Gadoxetate (injection)	9
 Imiquimod (cream)	 7
Iodixanol (injection)	9
Iohexol (injection)	9
Iomeprol (injection).....	9

Iopamidol (injection)	9
Ioversol (injection)	9
Levonorgestrel (tablets).....	6
Lidocaine (injection)	6
Lidocaine plus prilocaine (topical)	6
Lidocaine (spray).....	6
Medroxyprogesterone acetate (injection IM)	6
Medroxyprogesterone acetate (injection SC)	6
Metronidazole (tablets).....	7
Midazolam (buccal)	5
Nitrofurantoin (tablets and capsules).....	8
Omeprazole (tablets)	10
PEP	7
Podophyllotoxin (solution)	7
PrEP	7
Progestogen Only Contraceptive (tablets).....	6
Progestogen-Only (IUS)	6
Terbutaline (injection).....	10
Tranexamic acid (injection)	5
Ulipristal acetate (tablets).....	6

Ambulance Trusts

PGD templates in the national programme:

PGD template title	Released via SPS website
Flumazenil administration by registered Paramedics or Nurses for the complete or partial reversal of the central sedative effects of midazolam used for conscious sedation link	July 2022
Tranexamic acid administration by registered Paramedics and Nurses for treatment of severe haemorrhage link	V1 May 2020/V2 for use from May 2023 published Feb 2023
Buccal midazolam administration by registered Paramedics and Nurses for the management of seizures link	V1 May 2020/V2 for use from May 2023 published Feb 2023
Diazepam solution administration for injection by registered Paramedics and Nurses for the management of seizures link	V1 March 2020/V2 for use from March 2023 published Feb 2023
Diazepam rectal tubes administration by registered Paramedics and Nurses for the management of seizures link	V1 March 2020/V2 for use from March 2023 published Feb 2023
Diazepam emulsion for injection administration by registered Nurses for the management of seizures	Retired March 2023 due to lack of need

Reproductive Health

PGD templates in the national programme:

PGD template title	Released via SPS website
Levonorgestrel 1500micrograms for emergency contraception link	V1 March 2020/V2 for use from March 2023 published November 2022
Ulipristal acetate 30mg tablet for emergency contraception link	
Progestogen Only Contraceptive Pills (POP) link	V1 April 2020/V2 for use from April 2023 published Jan 2023
Combined Hormonal Contraceptives (CHC) – COC, CHC ring, CHC patch link	V1 April 2020/V2 for use from April 2023 published Jan 2023
Etonorgestrel (Nexplanon®) subdermal implant	October 2020
Lidocaine Hydrochloride Injection BP 1% w/v to facilitate subdermal implant insertion and/or removal link	October 2020
Medroxyprogesterone acetate Injection 150mg/mL (DPMA) intramuscular injection link	May 2020
Medroxyprogesterone acetate (MPA) 104mg in 0.65mL subcutaneous injection link	V1 May 2020/V2 for use from May 23 published January 2023
Intra-Uterine System (IUS) Progestogen-Only link	August 2020
Protocol – Lidocaine 10% spray for IUC insertion/removal link	January 2023
Protocol – Lidocaine plus prilocaine cream for IUC insertion/removal link	January 2023

PGD templates not included within the national programme:

Condition/clinical area	Rationale
IUD (non drug eluting)	PGD not required as medical devices – see https://www.sps.nhs.uk/articles/when-patient-group-directions-pgds-are-not-required-guidance-on-when-pgds-should-not-be-used-and-advice-on-alternative-mechanisms-for-supply-and-administration-of-medicines/

Sexual health

PGD templates in the national programme:

PGD template title	Released via SPS website
Azithromycin for the treatment of uncomplicated genital Chlamydia trachomatis and non-gonococcal/non-specific urethritis/Mycoplasma genitalium link	V1 November 2020/V2 for use from April 2023 published January 2023
Doxycycline for the treatment of uncomplicated genital chlamydia trachomatis and non-gonococcal/non-specific urethritis link	V1 November 2020/V2 for use from April 2023 published January 2023
Metronidazole for treatment of Bacterial vaginosis and trichomonas vaginalis	November 2020
Ceftriaxone with Lidocaine link	November 2020
Clotrimazole cream for symptomatic treatment of vulvo-vaginal candidiasis link	November 2020
Clotrimazole pessaries for treatment of vulvo-vaginal candidiasis link	November 2020
Fluconazole for treatment of vulvo-vaginal candidiasis link	November 2020
Aciclovir for treatment of genital herpes simplex infection link	February 2021
Imiquimod for treatment of ano-genital warts link	February 2021
Podophyllotoxin for treatment of ano-genital warts link	February 2021
Pre-exposure prophylaxis for HIV (PrEP) link	June 2020
Post-exposure prophylaxis for HIV (PrEP) link	V1 August 2021/V2 for use from June 2023 published January 2023

Antimicrobials

PGD templates in the national programme:

PGD template title	Released via SPS website
Benzyloxyphenoxymethyl penicillin for the treatment of suspected bacterial meningitis or meningococcal septicaemia link	January 2021
Nitrofurantoin for the management of UTI link	January 2023
Trimethoprim for the management of UTI link	January 2023

PGD templates not included within the national programme:

Condition/clinical area	Rationale
Dental infections	GPs are advised not to prescribe antibiotics for dental infections but to refer patients presenting with dental related infection to dental services for review and appropriate management. Given this position it would be inappropriate for PGDs to be produced for dental infection management by other healthcare professionals. https://www.bma.org.uk/advice/employment/gp-practices/quality-first/manage-inappropriate-workload/patients-presenting-with-possible-dental-problems
Lyme's disease	NICE guidance available to support treatment pathways but condition is considered to be specialist and requiring patient testing - stakeholder group consider there would be opportunities within the patient pathway for prescribing of antimicrobial therapy to be undertaken and that the treatment of Lyme's disease under a PGD not to be appropriate.
Sepsis (neutropenic and non-neutropenic)	No national guidance to support antimicrobial choices. Local PGD production may be considered against local antimicrobial guidance and microbiological advice.
UTI in catheterised patients	Potentially complex clinical situation requiring clinical review and prescribing. Stakeholder group do not support the use of a PGD to manage UTI in this patient group.
UTI in men	Potentially complex clinical situation requiring clinical review and prescribing. Stakeholder group do not support the use of a PGD to manage UTI in this patient group.
UTI in children	Potentially complex clinical situation requiring clinical review and prescribing. Stakeholder group do not support the use of a PGD to manage UTI in this patient group.

Imaging contrast

PGD templates in the national programme:

PGD template title	Released via SPS website
Iohexol (e.g. Omnipaque 140®, Omnipaque 240®, Omnipaque 300®, Omnipaque 350®) administration by registered Radiographers for imaging investigations and procedures link	November 2021
Iopamidol (e.g. Niopam 300®/Niopam 370®) administration by registered Radiographers for imaging investigations and procedures link	November 2021
Ioversol (e.g. Optiray® 270mg/ml, 300mg/ml, 320mg/ml, 350mg/ml) administration by registered Radiographers for imaging investigations and procedures link	November 2021
Iodixanol (e.g. Visipaque®) administration by registered Radiographers for imaging investigations and procedures link	November 2021
Iomeprol (e.g. Iomeron®) administration by registered Radiographers for imaging investigations and procedures link	November 2021
Gadobutrol (e.g. Gadovist®) administration by registered Radiographers for Magnetic Resonance Imaging (MRI) investigations and procedures link	January 2022
Gadoteric acid meglumine 0.5mmol/ml (e.g. Dotarem®, Clariscan®, Dotagraf®, Cyclolux®) administration by registered Radiographers for Magnetic Resonance Imaging (MRI) investigations and procedures link	January 2022
Gadoteridol 0.5mmol/ml (e.g. ProHance®) administration by registered Radiographers for Magnetic Resonance Imaging (MRI) investigations and procedures link	January 2022
Gadobenate dimeglumine (e.g. MultiHance®) administration by registered Radiographers for Magnetic Resonance Imaging (MRI) investigations and procedures link	January 2022
Gadoxetate disodium (e.g. Primovist®) administration by registered Radiographers for Magnetic Resonance Imaging (MRI) investigations and procedures link	January 2022

Preventative Medicines in Pregnancy

PGD templates in the national programme:

PGD template title	Released via SPS website
Aspirin 75mg tablet supply for individuals at high risk of pre-eclampsia link	February 2022
Folic acid 5mg tablet supply to reduce the risk of neural tube defect or to compensate for the increased demand for folate during pregnancy link	February 2022
Administration of subcutaneous terbutaline sulfate for the reduction of contraction frequency in individuals in labour link	January 2023
Administration of benzylpenicillin to individuals in labour where there has been an identified risk of early onset Group B Streptococcal (GBS) infection developing in the neonate link	January 2023
Protocol – omeprazole tablet administration and/or supply by midwives	In development